CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).

NCT Number	NCT07464951
Lead Sponsor	Stephan Grupp MD PhD Collaborators: Children's Hospital of Philadelphia
Conditions	Acute Myeloid Leukemia (AML)
Enrollment	30 participants
Start Date	2026-05-14
Primary Completion	2029-05-14 (estimated)
Study Completion	2030-05-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-07